FloodLAMP FDA EUA COVID-19 Retrospectives and Criticisms -- Post-2022 Research Report Research report identifying post-2022 retrospectives, evaluations, and criticisms of the FDA's Emergency Use Authorization (EUA) process during COVID-19, covering government oversight reports (HHS OIG, GAO, FDA), legislative responses, NGO and professional association critiques, and academic analyses, with archive-ready metadata for each source. ai file regulatory reg-articles-misc _AI_fda-eua-covid-retrospectives_post2022_report.md regulatory/reg-articles-misc/_AI_fda-eua-covid-retrospectives_post2022_report.md 2026_02_26 Created by ChatGPT 5.2 Pro Extended during archive preparation. **NOT HUMAN VERIFIED - MAY CONTAIN ERRORS** Research report on retrospectives and criticisms of the FDA's EUA process during COVID-19, focusing on post-2022 publications from government oversight agencies, legislative bodies, NGOs, professional associations, and academics. Key source documents: FloodLAMP project description and reg-articles-misc archive bundle. EUA, diagnostics, FDA, COVID-19, retrospective, oversight, policy-critique, pandemic-preparedness md CC BY 4.0 - https://creativecommons.org/licenses/by/4.0/ 2992 6354 gfile-url xfile-github-download-url pdf-gdrive-url pdf-github-url github-markdown-url github-markdown-download-url web-pdf-url web-slides-url youtube-url web-url